QDEL

On October 5, 2026, QDEL's stock price surged approximately 12.72% with a significant increase in trading volume. As of October 1, 2026, the share price was $10.40, representing a substantial decline of 66.74% from $31.25 on October 1, 2025. On September 23, 2026, QuidelOrtho Corp entered Amendment No. 1 to its Credit Agreement. S&P Global Ratings revised QuidelOrtho's outlook to negative from positive on August 19, 2026, attributing this to persistent headwinds in the company's China business and soft demand for respiratory products. Following its Q2 2026 earnings report on August 6, 2026, the company's stock price experienced a significant drop because QuidelOrtho substantially lowered its full-year fiscal 2026 financial guidance, despite beating analyst estimates for adjusted earnings per share and revenue, due to demand headwinds, proposed IVD pricing guidelines in China, a more cautious view of the respiratory season, and waning COVID-19 testing demand. On July 23, 2026, the Kaskela Law Firm announced an investigation into QuidelOrtho Corp. In April 2026, the company announced preliminary unaudited revenue for the first quarter of 2026, which was negatively impacted by a weaker respiratory season in the U.S., slower distributor sales in China due to proposed reimbursement rate reductions, and delayed EMEA orders caused by the Middle East conflict. QuidelOrtho Corporation was dropped from the Russell 3000E Growth Benchmark on June 29, 2026.